

PDE-5 Inhibitors: Clinical Points

Current Drug Targets

16, 420-426

DOI: 10.2174/1389450115666141111111301

Citation Report

#	ARTICLE	IF	CITATIONS
1	Non-alcoholic fatty liver disease and dyslipidemia: An update. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1109-1123.	1.5	363
2	Approach to Erectile Dysfunction in Patients with Hypertension and Coronary Artery Disease. , 2016, , 309-327.		2
4	Rapid Screening of Potential Phosphodiesterase Inhibitors from the Roots of <i>Ilex pubescens</i> Hook. et Arn. Using a Combination of Ultrafiltration and LC-MS. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-8.	0.5	5
5	Homocysteine and Non-Cardiac Vascular Disease. <i>Current Pharmaceutical Design</i> , 2017, 23, 3224-3232.	0.9	24
6	Tadalafil once daily: Narrative review of a treatment option for female sexual dysfunctions (FSD) in midlife and older women. <i>Archivio Italiano Di Urologia Andrologia</i> , 2017, 89, 7.	0.4	5
7	Herbal Dietary Supplements for Erectile Dysfunction: A Systematic Review and Meta-Analysis. <i>Drugs</i> , 2018, 78, 643-673.	4.9	30
8	Nanomedicine as a potential approach to empower the new strategies for the treatment of preeclampsia. <i>Drug Discovery Today</i> , 2018, 23, 1099-1107.	3.2	27
10	Increased Use of Medications for Erectile Dysfunction in Men With Ulcerative Colitis and Crohn's Disease Compared to Men Without Inflammatory Bowel disease: A Nationwide cohort Study. <i>American Journal of Gastroenterology</i> , 2018, 113, 1355.	0.2	29
11	PDE5A Suppresses Proteasome Activity Leading to Insulin Resistance in C2C12 Myotubes. <i>International Journal of Endocrinology</i> , 2019, 2019, 1-10.	0.6	11
13	Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue. <i>International Journal of Endocrinology</i> , 2020, 2020, 1-8.	0.6	9
14	A Prospective Clinical Study of a Prosexual Nutrient: Nano Leo for Evaluation of Libido, Erection, and Orgasm in Indian Men with Erectile Dysfunction. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-7.	0.5	1
15	Pharmacology and perspectives in erectile dysfunction in man. , 2020, 208, 107493.		55
16	Hyperhomocysteinemia: Focus on Endothelial Damage as a Cause of Erectile Dysfunction. <i>International Journal of Molecular Sciences</i> , 2021, 22, 418.	1.8	17
17	Translational research in drug discovery: Tiny steps before the giant leap. , 2021, , 347-369.		0
18	The Effect of Tadalafil on Renal Fibrosis Induced by Ureteral Obstruction. <i>West Indian Medical Journal</i> , 0, , .	0.4	0
19	Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?. <i>Current Vascular Pharmacology</i> , 2020, 19, 301-312.	0.8	8
20	The pharmacological management of erectile dysfunction – Update 2016. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2016, 58, 10-14.	0.2	0
23	Sex-Based Differences in the Biodistribution of Nanoparticles and Their Effect on Hormonal, Immune, and Metabolic Function. <i>Advanced NanoBiomed Research</i> , 2022, 2, .	1.7	9

#	ARTICLE	IF	CITATIONS
24	The pharmacological management of erectile dysfunction. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2015, 57, 4.	0.2	1